SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

National Association for Continuing Education
Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Sandhya Khurana, MD
Associate Professor, Pulmonary and Critical Care Medicine
Co-Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
University of Rochester School of Medicine
Rochester, NY

: Managing Alpha-1 Antitrypsin Deficiency and COPD: Incorporating the Latest GOLD Guidelines into Practice
Activity/Course #:
: NCME377
: Free
Release/Start Date:
: Jun 01 2019
Expiration Date:
: May 31 2020
: Pulmonology
Target Audience:
: Pulmonologist, Primary Care Physicians, Nurse Practitioners, Physician Assistants
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.50 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Alpha-1 antitrypsin deficiency (AATD) is characterized by low serum levels of alpha-1 antitrypsin (AAT), a serine protease inhibitor responsible for inhibiting the proteolytic enzyme elastase. The clinical effects of AATD are most frequently found in the lungs, where AATD is associated with an increased risk of developing chronic obstructive pulmonary disease (COPD). Severe AATD poses a significant threat to health, with airflow obstruction being a major determinant of mortality. Over 250,000 individuals in the United States may have AATD, but the disease often remains unrecognized or undertreated.

This activity will examine the pathophysiology of AATD, the clinical significance of laboratory test results, strategies to enhance detection, and the latest treatment options.

This activity was recorded at the Conversations in Pulmonology 2019 live broadcast, and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Discuss the pathophysiology of Alpha-1 antitrypsin deficiency (AATD) and its impact on chronic obstructive pulmonary disease (COPD) risk
  2. Interpret the clinical significance of laboratory test results for AATD
  3. Discuss treatment options for AATD and latest GOLD guideline recommendations
  4. Discuss strategies to enhance detection and treatment of AATD in clinical practice


How to obtain the CME Certificate
  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1 contact hour of continuing education which includes 0.50 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Dr. Rahaghi is a consultant for Grifols and Takeda Pharmaceuticals.

Dr. Khurana has served as a Principal Investigator for GlaxoSmithKline and Sanofi.

Activity Planning Committe
Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Daniela Hiedra, BA, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.

Alan Goodstat, LCSW, has no relationships to disclose.
Commercial Support
This educational activity is supported by an independent medical educational grant from Shire.